Tamiflu Latest Roche-Sponsored Tamiflu Review Enters the Fray Janis C. Kelly February 10, 2015 A meta-analysis of individual patient data from nine randomized controlled trials that compared oseltamivir (Tamiflu, Roche) with placebo found a modest reduction in symptom duration and respiratory complications. But critics caution that those benefits have to be weighed against an increase in adverse effects and point out that the new analysis was funded by Roche through an outside group.
Although the Centers for Disease Control and Prevention currently recommends prescribing antiviral agents to high-risk individuals with suspected influenza infections, the effectiveness of oseltamivir remains a matter of debate. In 2014, Tom Jefferson, MD, and researchers from the Cochrane Collaboration Acute Respiratory Infections Group reported a systematic review of 23 randomized, controlled trials…
